Why Aphria (TSX:APHA) Is Canada’s Top Pot Stock to Buy Today

Buy Aphria Inc. (TSX:APHA)(NYSE:APHA) today and profit from growing demand for legal marijuana.

Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Marijuana stocks continue to take a hammering, as the Canadian regulator cracks down, and many companies fail to deliver value as promised. Leading cultivator Canopy Growth has lost a whopping 47% since the start of 2019, while smaller cannabis stocks have suffered even larger losses. One cultivator that appears well positioned to not only survive the latest trials and tribulations besetting the burgeoning global legal cannabis industry but will emerge with greater market share is Aphria (TSX:APHA)(NYSE:APHA).

Improved results

The company was roughly handled by the market after a scathing research report was released toward the end of 2018, which essentially implied that the company was fraudulent. This sparked a rout of Aphria’s stock, which in turn saw significant management changes at the company, as it battled to regain investor confidence.

Since then Aphria has reported some solid results, revitalizing its stock. It’s down by 28% for the year to date, which is less than half of many other cannabis stocks. There is every indication that Aphria will rally strongly once the legal marijuana industry starts to consolidate and the fallout from earlier excesses comes to an end.

For its fiscal first quarter 2019, Aphria reported that revenue from cannabis products had almost tripled compared to the equivalent period in 2018 to $35 million and total revenue had grown to $126 million. This saw gross operating profit more than triple to $45 million, while adjusted EBITDA was $1.3 million compared to a $399,000 loss a year earlier. The strength of Aphria’s performance saw it report a net profit of $16 million, which was the second consecutive quarterly profit in an industry where many participants are operating at a loss.

Despite the fanfare surrounding Canopy and its alliance with liquor giant Constellation Brands, it continues to be hammered by the market because of its large losses. For the fiscal second quarter 2019, Canopy reported a massive $375 million loss, and that came on the back of a whopping $1.3 billion fiscal first-quarter loss.

Aphria’s key strength is its global distribution network, which reduces its dependence on an increasingly saturated Canadian legal marijuana market. There are fears that Canada’s market is over supplied, and that the situation will become worse, as domestic cultivation continues to grow. Even the legalization of cannabis derivatives and edibles won’t be enough to reduce the growing supply glut.

Aphria has established a strategic global platform, including a significant presence in Germany, which is considered to be one of the most lucrative medical marijuana markets globally. It is also focused on expanding its cultivating capacity forecasting that it can produce up to 255,000 kilograms of cannabis annually at its Canadian facilities alone once the Aphria Diamond operation is approved by Health Canada. That endows Aphria with considerable flexibility and the capability to meet growing global demand for legal cannabis products.

The cultivator also finished the fiscal second quarter with a solid balance sheet, holding $449 million in cash and a manageable $461 million of debt. This will allow Aphria to make accretive acquisitions, thereby boosting its market share, once the industry starts to rationalize.

Foolish takeaway

Aphria has emerged as a market leader among cannabis stocks with it being one of the few Canadian legal marijuana cultivators to attain profitability. The company is poised to continue growing as sales rise, and it taps into what is thought will be a $150 billion global legal cannabis market by 2025. For the reasons discussed, Aphria is shaping up as the best play on the growing global demand for legal marijuana.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Matt Smith has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

Why I’m Considering Canopy Growth Stock For My RRSP

As the cannabis industry grows, adding Canopy Growth stock to my RRSP will give me access to massive upside.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock Jumps 20%: Here’s What Happened

Canopy Growth stock (TSX:WEED)(NASDAQ:CGC) popped 20% on Monday from an announcement made by another cannabis producer.

Read more »

Retirement plan
Dividend Stocks

4 Stocks That Could Turn $100,000 Into $500,000 by the Time You Retire

Companies such as Brookfield Asset Management have the potential to consistently beat the broader markets and deliver stellar returns to…

Read more »

Cannabis Stocks

TFSA Investors: 2 U.S. Stocks I’m Never Selling

Canadians looking to diversify their portfolios and gain exposure to U.S. stocks can purchase shares of high-growth companies such as…

Read more »

A cannabis plant grows.
Cannabis Stocks

Aurora Cannabis (TSX:ACB) Keeps Burning Cash as Revenue Falls

Aurora Cannabis (TSX:ACB)(NASDAQ:ACB) is still losing money. Its revenue is declining, too.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Canopy Growth Stock Climbed as Much as 20% on Monday

A glimmer of hope from the U.S. Congress may lead to renewed interest in marijuana investing.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Friday, July 15

A continued selloff in metals prices is likely to pressure the commodity-heavy TSX Composite benchmark at the open today.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

With the Cannabis Industry Trading Ultra-Cheap, Organigram Stock Looks Like a Screaming Buy!

After selling off for years, Organigram stock now offers tonnes of value and is easily one of the best cannabis…

Read more »